Jos Kitzen

966 total citations
25 papers, 625 citations indexed

About

Jos Kitzen is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Jos Kitzen has authored 25 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 5 papers in Cardiology and Cardiovascular Medicine and 3 papers in Molecular Biology. Recurrent topics in Jos Kitzen's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (5 papers) and Peptidase Inhibition and Analysis (5 papers). Jos Kitzen is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (5 papers) and Peptidase Inhibition and Analysis (5 papers). Jos Kitzen collaborates with scholars based in Netherlands, Finland and United Kingdom. Jos Kitzen's co-authors include Jaap Verweij, Maja J.A. de Jonge, Guus Fons, Monique H. W. Frings‐Dresen, Peter W. Plaisier, Walter J. Loos, Angela G. E. M. de Boer, Jos Verbeek, Monique M.E.M. Bos and Sietske J. Tamminga and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jos Kitzen

24 papers receiving 609 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jos Kitzen Netherlands	15	314	187	79	70	66	25	625
Antonella Savarese Italy	20	587 1.9×	252 1.3×	29 0.4×	39 0.6×	45 0.7×	66	1.5k
Zsuzsanna Németh Hungary	18	171 0.5×	343 1.8×	64 0.8×	26 0.4×	81 1.2×	46	871
Jawaid Younus Canada	17	276 0.9×	99 0.5×	36 0.5×	60 0.9×	16 0.2×	54	823
Frederike K. Engels Netherlands	13	294 0.9×	138 0.7×	118 1.5×	25 0.4×	67 1.0×	17	681
Isabel Blancas Spain	11	269 0.9×	89 0.5×	32 0.4×	21 0.3×	32 0.5×	45	508
Stacie C. Jeter United States	16	382 1.2×	271 1.4×	32 0.4×	91 1.3×	25 0.4×	37	1000
Hege Edvardsen Norway	20	463 1.5×	657 3.5×	36 0.5×	96 1.4×	121 1.8×	38	1.3k
Kun-Ming Rau Taiwan	14	335 1.1×	194 1.0×	17 0.2×	24 0.3×	84 1.3×	23	724
Gilles Fournier Denmark	11	116 0.4×	150 0.8×	110 1.4×	49 0.7×	23 0.3×	18	518
Ellen Copson United Kingdom	21	774 2.5×	430 2.3×	19 0.2×	49 0.7×	59 0.9×	71	1.5k

Countries citing papers authored by Jos Kitzen

Since Specialization

Citations

This map shows the geographic impact of Jos Kitzen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos Kitzen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos Kitzen more than expected).

Fields of papers citing papers by Jos Kitzen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jos Kitzen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos Kitzen. The network helps show where Jos Kitzen may publish in the future.

Co-authorship network of co-authors of Jos Kitzen

This figure shows the co-authorship network connecting the top 25 collaborators of Jos Kitzen. A scholar is included among the top collaborators of Jos Kitzen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jos Kitzen. Jos Kitzen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kitzen, Jos, et al.. (2024). Surgeon reported treatment choices for AO type B and C thoracolumbar fractures without neurological deficits: An expert survey. Injury. 55(3). 111389–111389. 1 indexed citations

Hooning, Maartje J., Carolien H. M. van Deurzen, Jan C. Drooger, et al.. (2023). The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study. Cancer. 130(6). 927–935. 2 indexed citations

Rier, Hánah N., Joost van Rosmalen, Peter E. Westerweel, et al.. (2022). Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with Cancer. The Oncologist. 27(11). e878–e888. 11 indexed citations

Steenbruggen, Tessa G., Hánah N. Rier, Jos Kitzen, et al.. (2022). The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction. International Journal of Cancer. 151(4). 616–622. 5 indexed citations

Steenbruggen, Tessa G., Joost van Rosmalen, Hánah N. Rier, et al.. (2021). Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?. Breast Cancer Research and Treatment. 186(3). 851–862. 20 indexed citations

Kofflard, Marcel J.M., Jasper J. Brugts, Marc C. J. M. Kock, et al.. (2021). 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab. Cardiovascular Ultrasound. 19(1). 35–35. 6 indexed citations

Jager, Agnes, Marcel J.M. Kofflard, Jasper J. Brugts, et al.. (2020). Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. The Breast. 52. 33–44. 30 indexed citations

Tamminga, Sietske J., Jos Verbeek, Monique M.E.M. Bos, et al.. (2019). Two-Year Follow-Up of a Multi-centre Randomized Controlled Trial to Study Effectiveness of a Hospital-Based Work Support Intervention for Cancer Patients. Journal of Occupational Rehabilitation. 29(4). 701–710. 15 indexed citations

Steenbruggen, Tessa G., Carolien H. Smorenburg, Hánah N. Rier, et al.. (2019). Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?. Breast Cancer Research and Treatment. 178(3). 597–605. 15 indexed citations

10.

Hellemond, Irene E.G. van, Ingeborg J. H. Vriens, Petronella G.M. Peer, et al.. (2017). Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. JNCI Journal of the National Cancer Institute. 109(12). 22 indexed citations

11.

Tamminga, Sietske J., Jos Verbeek, Monique M.E.M. Bos, et al.. (2013). Effectiveness of a Hospital-Based Work Support Intervention for Female Cancer Patients – A Multi-Centre Randomised Controlled Trial. PLoS ONE. 8(5). e63271–e63271. 67 indexed citations

12.

Tamminga, Sietske J., Angela G. E. M. de Boer, Monique M.E.M. Bos, et al.. (2012). A Hospital-Based Work Support Intervention to Enhance the Return to Work of Cancer Patients: A Process Evaluation. Journal of Occupational Rehabilitation. 22(4). 565–578. 38 indexed citations

13.

Jonge, Maja J.A. de, Herlinde Dumez, Jos Kitzen, et al.. (2011). Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. European Journal of Cancer. 47(9). 1328–1335. 18 indexed citations

14.

Baird, Richard D., Jos Kitzen, Paul A. Clarke, et al.. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(6). 1430–1437. 33 indexed citations

15.

Kitzen, Jos, Maja J.A. de Jonge, C. B. H. W. Lamers, et al.. (2009). Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. European Journal of Cancer. 45(10). 1764–1772. 77 indexed citations

16.

Attard, Gerhardt, Jos Kitzen, Sarah P. Blagden, et al.. (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. British Journal of Cancer. 97(10). 1338–1343. 52 indexed citations

17.

Jong, Floris A. de, Jessica M. van der Bol, Ron H.J. Mathijssen, et al.. (2007). Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity. Cancer Biology & Therapy. 6(9). 1364–1370. 22 indexed citations

18.

Engels, Frederike K., Floris A. de Jong, Alex Sparreboom, et al.. (2007). Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel. The Oncologist. 12(3). 291–300. 65 indexed citations

19.

Jong, Floris A. de, Jos Kitzen, Peter de Bruijn, Jaap Verweij, & Walter J. Loos. (2006). Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biology & Therapy. 5(9). 1105–1110. 15 indexed citations

20.

Attard, Gerhardt, Jos Kitzen, Johann S. de Bono, et al.. (2005). A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3166–3166. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact